Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

IPH5201

IPH5201 is a human IgG1 monoclonal antibody (mAb) targeting ENTPD1/CD39. IPH5201 accumulates immunostimulatory ATP released by tumor cells treated with combination chemotherapy (CT) and reduces immunosuppressive Ado levels in the tumor microenvironment (TME). IPH5201 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control.

Product Specifications

UNSPSC

12352203

Target

NTPDase

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

I[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5].[PH5]

References & Citations

[1]Barlesi F, et al. 1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE) [J]. Annals of Oncology, 2023, 34: S744.

Shipping Conditions

Room temperature

Scientific Category

Inhibitory Antibodies

Clinical Information

No Development Reported

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)
MBS1237117-01 0.02 mg (E-Coli)

Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)

Sign In for Pricing
View Details
Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)
MBS1237117-02 0.02 mg (Yeast)

Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)

Sign In for Pricing
View Details
Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)
MBS1237117-03 0.1 mg (E-Coli)

Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)

Sign In for Pricing
View Details
Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)
MBS1237117-04 0.1 mg (Yeast)

Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)

Sign In for Pricing
View Details
Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)
MBS1237117-05 0.02 mg (Baculovirus)

Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)

Sign In for Pricing
View Details
Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)
MBS1237117-06 0.02 mg (Mammalian-Cell)

Recombinant Clostridium botulinum tRNA modification GTPase MnmE (mnmE)

Sign In for Pricing
View Details